Efficacy and safety of lenvatinib plus everolimus in metastatic renal cell carcinoma after immune checkpoint and VEGFR tyrosine kinase inhibitors. This is an ASCO Meeting Abstract from the 2025 ASCO ...

IT IS well known that metastasis from a carcinoma of the kidney may occur many years after removal of the primary tumor. 1 2 3 The following example is reported because of the extraordinary ...

Patients with metastatic renal cell carcinoma staged pT1-4 Nx M1 were enrolled ... ultrasonic examinations and bone scintigraphy before and 12 week after the first immunization.

Belzutifan monotherapy in Chinese patients (pts) with von Hippel-Lindau (VHL) disease–associated tumors: Results of LITESPARK-015 study. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in Renal Cell Carcinoma) study underscore the critical role of tumor size ...

Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients ... can cause decreased renal function, the US Food and Drug ...

Opdivo plus Cometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.

Additionally, data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) show that patients receiving the combination therapy were more likely to maintain or improve ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at ...